6533b858fe1ef96bd12b632f

RESEARCH PRODUCT

Management of head and neck paragangliomas: review of 120 patients.

Wolf J. MannRonald G. AmedeeKonstantinos Papaspyrou

subject

AdultMalePathologymedicine.medical_specialtyAdolescentCarotid arteriesmedicine.medical_treatmentOutcome assessmentDeafnessParagangliomaYoung AdultNeoplasm RecurrencePostoperative ComplicationsParagangliomaOutcome Assessment Health CaremedicineHumansEmbolizationHead and neckChildAgedRetrospective StudiesAged 80 and overbusiness.industryMiddle Agedmedicine.diseaseEmbolization TherapeuticCranial Nerve DiseasesRadiation therapyOtorhinolaryngologyHead and Neck NeoplasmsFemaleRadiotherapy AdjuvantNeoplasm Recurrence LocalbusinessCarotid Artery Internal

description

Head and neck paragangliomas (PGL) are rare, mostly benign tumors. About 10% to 15% of PGL are caused by mutations in the succinate dehydrogenase genes B, C, or D and may appear multifocally.A retrospective review of 120 patients with 146 head and neck PGL, including 46 carotid body tumors (CBT), 13 vagal tumors, 55 jugulotympanic tumors (JTT), 25 tympanic tumors (TT) and 7 tumors in other locations are included. The internal carotid artery was preserved in 97.5% of CBT resections. Preservation of hearing was achieved in 92% of JTT and 88% of TT resections.According to our experience, the treatment of PGL must be individualized, taking into account the patient's age, medical condition, tumor site and size, multiple occurrences, and preexisting cranial nerve deficits. Tumor control is high whether treatment is by surgery or radiotherapy. Patients with solitary lesions whose disease is potentially resectable with acceptable morbidity are better treated surgically.

yearjournalcountryeditionlanguage
2008-10-31Headneck
10.1002/hed.20967https://pubmed.ncbi.nlm.nih.gov/18972432